US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tevogen Bio Holdings Inc.

0.0472

-0.0067-12.43%

Volume:401.88K

Turnover:18.53K

Market Cap:- -

PE:- -

High:0.0569

Open:0.0529

Low:0.0420

Close:0.0539

Loading ...

Overview Company News Filings

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

THOMSON REUTERS

Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations

Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (Hpv), Advancing Tvgn 920

THOMSON REUTERS

Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support

Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI Into Preclinical Processes, Accelerating Drug Development and Reducing Costs

THOMSON REUTERS

Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company

THOMSON REUTERS

Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas

Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating Drug Development

THOMSON REUTERS

Tevogen Bio to Provide Timelines Associated With Recently Announced Revenue Forecast and Updates on Operational Readiness This Week

THOMSON REUTERS

Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

THOMSON REUTERS

Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

THOMSON REUTERS

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

Tevogen Bio Thanks Warren Township for Proclamation Honoring CEO Dr. Ryan Saadi, Nobel Peace Prize Nomination, and the Company's Mission to Address Health Inequality

Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use

Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TVGNW/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TVGNW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGNW\",,,,,undefined,":{"symbol":"TVGNW","market":"US","secType":"STK","nameCN":"Tevogen Bio Holdings Inc.","latestPrice":0.0472,"timestamp":1743537600000,"preClose":0.0539,"halted":0,"volume":401884,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":-0.0067,"latestTime":"04-01 16:00:00 EDT","open":0.0529,"high":0.0569,"low":0.042,"amount":18525.306425,"amplitude":0.276438,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743580800000},"marketStatusCode":0,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0539,"volumeRatio":1.366266},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TVGNW\",,,,,undefined,":{"symbol":"TVGNW","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.366266,"shares":0,"dividePrice":0,"high":0.0569,"amplitude":0.276438,"preClose":0.0539,"low":0.042,"week52Low":0.0099,"pbRate":"--","week52High":0.1499,"institutionHeld":0,"latestPrice":0.0472,"eps":0,"divideRate":0,"volume":401884,"delay":0,"ttmEps":0,"open":0.0529,"prevYearClose":0.054,"prevWeekClose":0.0579,"prevMonthClose":0.0539,"prevQuarterClose":0.0539,"fiveDayClose":0.0579,"twentyDayClose":0.0724,"sixtyDayClose":0.06},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TVGNW\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2482645853","title":"Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2482645853","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482645853?lang=en_us&edition=fundamental","pubTime":"2024-11-09 04:36","pubTimestamp":1731098208,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nTUA5FVRKZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":0},{"id":"2482458288","title":"Tevogen Bio Nears Finalization of Agreement to Enhance R&D and Manufacturing Capabilities; $36 Million Line of Credit Available for Continued Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2482458288","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482458288?lang=en_us&edition=fundamental","pubTime":"2024-11-09 04:36","pubTimestamp":1731098160,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Nov. 08, 2024  -- Tevogen Bio  , a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, nears finalization of agreement with CD8 Technology for a turn-key facility intended to support both pre-clinical research and GMP manufacturing capabilities, staffed by Tevogen.In tandem with this announcement, Tevogen Bio reaffirms its existing agreement which provides access to a $36 million line of credit to ensure ongoing operations and fuel future growth.Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadership believes that accessible personalized therapeutics are the next frontier of medicine, and that disruptive business models are required to susta","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-nears-finalization-agreement-203600118.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TVGNW","TVGN"],"gpt_icon":1},{"id":"2481507727","title":"Tevogen Bio Leverages Microsoft Partnership to Deliver Machine Learning Based Target Identification to Address Human Papilloma Virus (Hpv), Advancing Tvgn 920","url":"https://stock-news.laohu8.com/highlight/detail?id=2481507727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481507727?lang=en_us&edition=fundamental","pubTime":"2024-11-05 22:27","pubTimestamp":1730816868,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nTUA2RMS6S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","BK4533","BK4588","IE00BKPKM429.USD","IE0004091025.USD","IE00B3SWFQ91.USD","BK4516","IE000W1ABFV2.USD","IE00B19Z9505.USD","BK4525","IE00B1BXHZ80.USD","IE00BJJMRY28.SGD","BK4538","IE00BK4W5L77.USD","BK4577","IE00BJTD4V19.USD","IE00BBT3K403.USD","BK4097","IE00B4YYXB79.USD","BK4567","BK4504","BK4527","BK4532","IE00BKDWB100.SGD","IE00B19Z8X17.USD","IE00BK4W5M84.HKD","MSFT","TVGN","IE0034235295.USD","IE000ITXATA3.USD","IE00B5949003.HKD","IE0004445015.USD","BK4535","IE00B5TLWC47.USD","IE00B1XK9C88.USD","IE0005OL40V9.USD","IE0009356076.USD","IE0004086264.USD","IE00BJJMRX11.SGD","BK4139","BK4528","IE0004445239.USD","IE00BFSS7M15.SGD","BK4503","IE00B3S45H60.SGD","BK4579","BK4585","BK4592","GB00BDT5M118.USD","IE00BHPRN162.USD"],"gpt_icon":0},{"id":"2481552305","title":"Tevogen Bio Announces Appointment of Anthony Tarantino as Patient Advocate to Enhance Community Engagement and Patient Support","url":"https://stock-news.laohu8.com/highlight/detail?id=2481552305","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481552305?lang=en_us&edition=fundamental","pubTime":"2024-11-05 03:36","pubTimestamp":1730748960,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Nov. 04, 2024  -- Tevogen Bio  , a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, is pleased to announce the appointment of Anthony Tarantino as its new Patient Advocate. Tarantino, a well-known leader in firefighter safety and community advocacy, brings extensive experience in representing and supporting high-risk groups, including first responders.Anthony Tarantino previously served as President of the Newark Fire Officers Union and Legislative Vice President of the Professional Firefighters Association of New Jersey . In these roles, Tarantino was instrumental in advancing policies for firefighter health, safety, and wellness. One of his notable achievements was in advocating for and securing the passage of legislation in New Jersey mandating regular cancer screenings for firefighters. This legislation acknowledges the increased risk of cancer among firefighter","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-announces-appointment-anthony-193600845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","TVGNW","TVGN"],"gpt_icon":1},{"id":"2479003147","title":"Tevogen Bio Expands on Microsoft Partnership to Integrate Machine Learning and AI Into Preclinical Processes, Accelerating Drug Development and Reducing Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2479003147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479003147?lang=en_us&edition=fundamental","pubTime":"2024-10-31 22:54","pubTimestamp":1730386496,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241031:nTUA2RZSR0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B3S45H60.SGD","BK4577","BK4516","IE000W1ABFV2.USD","IE000YTNTUN2.SGD","MSFT","IE00B4JS1V06.HKD","IE00B7KXQ091.USD","IE00BFSS7M15.SGD","IE00B5949003.HKD","IE000KEQY171.SGD","BK4585","BK4567","BK4587","GB00BDT5M118.USD","IE0034235295.USD","IE00BKDWB100.SGD","IE00B3SWFQ91.USD","BK4592","GB00B4QBRK32.GBP","TVGN","TVGNW","IE0004445239.USD","BK4504","IE00B5TLWC47.USD","BK4139","BK4532","IE00BLSP4239.USD","IE0004445015.USD","BK4548","BK4588","BK4550","BK4527","IE0034235303.USD","BK4503","GB00B4LPDJ14.GBP","IE0009G5SDU7.USD","IE00B19Z8X17.USD","BK4097","IE00BJTD4N35.SGD","IE00BK4W5M84.HKD","IE0003U64NQ7.SGD","IE00BKPKM429.USD","BK4581","IE00B19Z9505.USD","BK4535","IE000ITXATA3.USD","BK4538","IE0004091025.USD","IE00BJJMRY28.SGD"],"gpt_icon":0},{"id":"2479255297","title":"Tevogen Bio Reports Nasdaq Listing Compliance as CEO Reaffirms His Commitment in Bridging the Information Gap About the Company","url":"https://stock-news.laohu8.com/highlight/detail?id=2479255297","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479255297?lang=en_us&edition=fundamental","pubTime":"2024-10-30 03:28","pubTimestamp":1730230112,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241029:nTUA9ZHDCS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","IE00BDRTCR15.USD","LU2210150020.SGD","IE00BDCRKT87.USD","IE00B3SWFQ91.USD","IE0034235188.USD","BK4516","IE00B19Z9505.USD","BK4525","IE00B1BXHZ80.USD","IE00BJJMRY28.SGD","IE00BK4W5L77.USD","IE00B7KXQ091.USD","IE00B4JS1V06.HKD","IE00BJTD4V19.USD","BK4554","IE00BFSS8Q28.SGD","IE0009G5SDU7.USD","BK4504","BK4527","BK4532","TVGN","IE00BK4W5M84.HKD","MSFT","IE0034235295.USD","IE000ITXATA3.USD","IE000KEQY171.SGD","IE00B5TLWC47.USD","BK4112","BK4548","IE0009356076.USD","IE00BLSP4239.USD","NDAQ","IE00BJTD4N35.SGD","BK4528","LU2095319765.USD","IE0004445239.USD","IE00BFSS7M15.SGD","BK4503","IE00BJLML261.HKD","IE00BKVL7J92.USD","IE00B775SV38.USD","LU2210149790.SGD","IE0034235303.USD","IE00B19Z8W00.USD","IE0003U64NQ7.SGD","BK4592","IE00B19Z8X17.USD","IE000YTNTUN2.SGD","IE00BFXG0V08.USD"],"gpt_icon":0},{"id":"2478796772","title":"Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas","url":"https://stock-news.laohu8.com/highlight/detail?id=2478796772","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478796772?lang=en_us&edition=fundamental","pubTime":"2024-10-26 05:34","pubTimestamp":1729892040,"startTime":"0","endTime":"0","summary":"Tevogen Bio’s recently shared forecast reflects its business plan of market entry by the end of 2026.“The rapid and cost-effective development of TVGN 489, achieved at a fraction of industry norms, strengthens my confidence in Tevogen’s innovative business model,” remarked Ryan Saadi, MD, MPH, Founder and CEO of Tevogen Bio, Nobel Peace Prize nominee, inventor of ExacTcell. “The positive clinical trial underscores TVGN 489’s potential, and it is my personal commitment that the company will do everything in its power to speed up the development process. I am pleased that the company was able to make progress to bridge any information gap and look forward to sharing other achievements in the coming weeks, particularly on the progress of Tevogen.AI.”Treatment of SARS-CoV-2 infection in patients with B cell hematologic cancer [part of Tevogen Bio Oncology forecast]. Treatment of Long COVID [part of Tevogen Bio Specialty Care forecast]. Tevogen is driven by a team of experienced industry le","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-provides-additional-guidance-213400649.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGNW","TVGN"],"gpt_icon":0},{"id":"2477581408","title":"Tevogen Bio’s Effort in Artificial Intelligence, Tevogen AI, Joins Microsoft for Startups, Begins Accelerating Drug Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2477581408","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477581408?lang=en_us&edition=fundamental","pubTime":"2024-10-23 20:35","pubTimestamp":1729686900,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"897a6e24b97610fa0649019bac9e26b6","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241023:nTUABJ7KZP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00B19Z8X17.USD","BK4535","BK4532","BK4548","IE00B19Z8W00.USD","MSFT","TVGN","IE0009356076.USD","IE00BKDWB100.SGD","IE00B3S45H60.SGD","BK4587","IE00B4YYXB79.USD","BK4567","IE00BK4W5M84.HKD","BK4576","IE0004445015.USD","BK4503","IE00B19Z9505.USD","IE00BLSP4239.USD","IE00BDCRKT87.USD","BK4516","IE00B1BXHZ80.USD","IE0005OL40V9.USD","BK4525","IE00BJJMRX11.SGD","BK4538","IE00B5TLWC47.USD","IE00BHPRN162.USD","IE00BKVL7J92.USD","BK4581","BK4566","IE000W1ABFV2.USD","BK4528","BK4579","BK4550","IE00BFSS7M15.SGD","TVGNW","IE0009G5SDU7.USD","IE000KEQY171.SGD","GB00BDT5M118.USD","IE000ITXATA3.USD","BK4527","IE000YTNTUN2.SGD","GB00B4QBRK32.GBP","IE0034235188.USD","GB00B4LPDJ14.GBP","IE00B775SV38.USD","BK4534","IE00B3SWFQ91.USD","IE00B7KXQ091.USD"],"gpt_icon":0},{"id":"2477369748","title":"Tevogen Bio to Provide Timelines Associated With Recently Announced Revenue Forecast and Updates on Operational Readiness This Week","url":"https://stock-news.laohu8.com/highlight/detail?id=2477369748","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477369748?lang=en_us&edition=fundamental","pubTime":"2024-10-23 02:30","pubTimestamp":1729621800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241022:nTUAC3NSVD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":0},{"id":"2477815832","title":"Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2477815832","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477815832?lang=en_us&edition=fundamental","pubTime":"2024-10-22 03:58","pubTimestamp":1729540704,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241021:nTUA9Z8ZTP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TVGN","BK4139","TVGNW"],"gpt_icon":0},{"id":"2476527480","title":"Tevogen CEO Expresses Gratitude for Unprecedented Public Support of Company’s Business Model of Commercial Success Through Patient Accessibility and Reaffirms His Commitment to Share Additional Details in the Coming Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2476527480","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476527480?lang=en_us&edition=fundamental","pubTime":"2024-10-19 10:46","pubTimestamp":1729305960,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Oct. 18, 2024  -- Tevogen Bio   is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers.Since being founded in 2020, Tevogen Bio has taken a unique approach to both drug development and managing its business operations. The company launched is proprietary ExacTcell technology, designed to create accessible and disease-specific cellular immunotherapies. Tevogen Bio received 3 U.S. patents, with an additional 9 patents pending, including 2 for Artificial Intelligence, and has filed 12 international applications. Additionally, the company reported positive proof-of-concept clinical trial data for the first clinical product of its proprietary technology.Tevogen is driven by a team of highly experienced industry leaders and distinguished scientists with drug development and global product launch experience. Tevogen’s leadershi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-ceo-expresses-gratitude-unprecedented-024600562.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGN","TVGNW","BK4139"],"gpt_icon":1},{"id":"2476312792","title":"Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow","url":"https://stock-news.laohu8.com/highlight/detail?id=2476312792","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476312792?lang=en_us&edition=fundamental","pubTime":"2024-10-17 21:32","pubTimestamp":1729171977,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241017:nTUAC4SVTP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TVGNW","TVGN"],"gpt_icon":0},{"id":"2476849120","title":"Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow","url":"https://stock-news.laohu8.com/highlight/detail?id=2476849120","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476849120?lang=en_us&edition=fundamental","pubTime":"2024-10-17 21:32","pubTimestamp":1729171920,"startTime":"0","endTime":"0","summary":"Total eligible patients in the US exceed 2 million.Treatment of SARS-CoV-2 infection in solid and hematologic cancer patients under active treatment.Reflects business philosophy of commercial success through patient accessibility.WARREN, N.J., Oct. 17, 2024  -- Tevogen Bio  , a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its oncology pipeline, projecting $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $10 billion and $14 billion. This forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.\"At Tevogen, we strive to turn our vision into reality ensuring our commitment translates into tangible results. Our priority is the well-being of cancer patients. ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-oncology-reports-top-133200378.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGNW","TVGN"],"gpt_icon":1},{"id":"2476197905","title":"Tevogen Bio Thanks Warren Township for Proclamation Honoring CEO Dr. Ryan Saadi, Nobel Peace Prize Nomination, and the Company's Mission to Address Health Inequality","url":"https://stock-news.laohu8.com/highlight/detail?id=2476197905","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476197905?lang=en_us&edition=fundamental","pubTime":"2024-10-17 04:30","pubTimestamp":1729110600,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Oct. 16, 2024  -- Tevogen Bio  , a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, expresses its heartfelt gratitude to the Township of Warren and its leadership for the recent proclamation honoring Tevogen’s efforts to address health inequality and the Nobel Peace Prize nomination of its CEO and founder, Ryan Saadi, MD, MPH.Tevogen is a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes, to develop off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, aiming to address the significant unmet needs of large patient populations. Tevogen leadership believes that sustainability and commercial success in the current era of healthcare rely on ensuring patient accessibility through advanced science and innovative business models. Tevogen has reported positive safety data from its proof-of-con","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/IsoryroWpPDtVbAgwzd4GQ--~B/aD0yNTkyO3c9MjAyODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/5bac3ad76d9638fd0f7f2be3176a75b4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/IsoryroWpPDtVbAgwzd4GQ--~B/aD0yNTkyO3c9MjAyODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/5bac3ad76d9638fd0f7f2be3176a75b4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-thanks-warren-township-203000872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGN","TVGNW"],"gpt_icon":1},{"id":"2475263194","title":"Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use","url":"https://stock-news.laohu8.com/highlight/detail?id=2475263194","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475263194?lang=en_us&edition=fundamental","pubTime":"2024-10-15 23:36","pubTimestamp":1729006560,"startTime":"0","endTime":"0","summary":"WARREN, N.J., Oct. 15, 2024  -- Tevogen Bio  , a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today highlights the publication of its phase I clinical trial data of TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes  immunotherapy, published by the journal Blood Advances in August of this year.Interventional arm patients, totaling twelve high-risk individuals, 50% of whom were immunocompromised, and 40% of whom were immunocompromised due to preexisting cancers, received a single infusion of one of four escalating doses of TVGN 489, a product containing 68.5% SARS-CoV-2-specific CD8+ CTLs/total cells.Symptom improvement and resolution in treatment arm patients were compared to an observational group of eighteen patients who received standard care, making a total of 30 study participants. Patients in the treatment group had symptom improve","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/BJRd_xndXodq.4BrmsL4bg--~B/aD02Mjg7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/927ad684614f9ce891b7a2e4313e2d86"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-highlights-publication-promising-153600306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company’s Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate Use","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGNW","BK4139","TVGN"],"gpt_icon":1},{"id":"2474484011","title":"Tevogen Bio Extends Pipeline Prioritizing Oncology and Long COVID","url":"https://stock-news.laohu8.com/highlight/detail?id=2474484011","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474484011?lang=en_us&edition=fundamental","pubTime":"2024-10-12 00:12","pubTimestamp":1728663120,"startTime":"0","endTime":"0","summary":"Developing therapeutic products that not only treat cancer but also enable oncology patients to maintain uninterrupted therapy.Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; the effect of the recent business combination with Semper Paratus Acquisition Corporation  on Tevogen’s business relationships, operating results, and business generall","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CECcfFydARk2toICyDT.Cg--~B/aD0xOTc5O3c9MTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/ccdc4ba6297ffe1451fd7a0b6c97348c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CECcfFydARk2toICyDT.Cg--~B/aD0xOTc5O3c9MTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/ccdc4ba6297ffe1451fd7a0b6c97348c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevogen-bio-extends-pipeline-prioritizing-161200198.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TVGNW","TVGN","BK4139"],"gpt_icon":0}],"pageSize":16,"totalPage":2,"pageCount":2,"totalSize":32}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TVGNW\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-02-15","symbol":"TVGNW","reason":null,"defaultRemindTime":1708007400000,"announcedDate":"2024-02-14","type":"delisting","dateTimestamp":1707973200000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TVGNW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TVGNW\",market:\"US\",delay:false,,,undefined,":{}}}